Organization Profile

You just read:

Samsung Bioepis Submits Marketing Authorization Application For SB2, A Remicade (Infliximab) Biosimilar Candidate, To The European Medicines Agency

News provided by

Samsung Bioepis

Mar 13, 2015, 08:00 ET